Table 1.
Background characteristics of patients
| Total n (%) | |
|---|---|
| Sex | |
| Men | 58 (60) |
| Women | 38 (40) |
| Age (y) | |
| median, range | 68.5, 26‐85 |
| Ann Arbor clinical stage | |
| I | 32 (33) |
| II | 20 (21) |
| III | 6 (6) |
| IV | 38 (40) |
| Opportunity of diagnosed gastric lesion | |
| Gastrointestinal symptom | 69 (72) |
| Medical examination | 8 (8) |
| Examination to investigate clinical stage | 19 (20) |
| IPI | |
| Low | 38 (40) |
| Low‐intermediate | 25 (26) |
| High‐intermediate | 13 (14) |
| High | 20 (21) |
| R‐IPI | |
| Very good | 10 (10) |
| Good | 53 (55) |
| Poor | 33 (34) |
| Serum LDH (IU/L) | |
| median, range | 233, 127‐3980 |
| Serum albumin (g/dL) | |
| median, range | 3.6, 1.8‐4.7 |
| Cycles of R‐CHOP | |
| 8 cycles | 47 (49) |
| 7 cycles | 3 (3) |
| 6 cycles | 38 (40) |
| Fewer than 6 cyclesa | 8 (8) |
IPI, International prognostic index; R‐IPI, Revised International prognostic index.
a
Including five cycles of R‐CHOP (n = 1), four cycles of R‐CHOP following one cycle of rituximab (n = 1), four cycles of R‐CHOP (n = 3), three cycles of R‐CHOP (n = 2), and one cycle of R‐CHOP (n = 1).